
"Syphilis Surge Across US Cities Amid Drug Shortages and Funding Cuts"
The US is experiencing a significant rise in syphilis cases, reaching a 27-year high, alongside a shortage of Bicillin L-A, the key antibiotic for treatment, particularly in pregnant women to prevent congenital syphilis. Public health officials are concerned about the impact on maternal and fetal health, with alternative treatments being less effective. Pfizer, the sole manufacturer of Bicillin L-A in the US, is struggling to meet demand but aims to resolve the shortage by spring 2024. The Biden administration has formed a taskforce and is providing strategic support to combat the outbreak, highlighting the importance of syphilis as a public health issue for 2024.













